KIT and hepatocellular carcinoma: Unfortunately, clinical trials of imatinib in HCC have all failed.179,180 Many inhibitors targeting c-Kit mutations have been approved, but the vast majority are multi-targeted kinase inhibitors.181 One of the targets of the current first-line targeted agents sorafenib and lenvatinib and the second-line therapies regorafenib and cabozantinib in the treatment of HCC includes c-Kit.